The Food and Drug Administration on Wednesday granted emergency use authorization to Novavax’s Covid-19 vaccine, opening up another option for adults who have not received immunization against the virus.
The vaccine, a two-dose series administered three weeks apart, is manufactured using a lab-made spike protein produced in insect cells and an adjuvant obtained from the bark of a tree native to Chile, offering a different and older vaccine technology than is used in the messenger RNA vaccines and Johnson & Johnson shot. It is authorized for people ages 18 and older as a primary series, meaning the shot is intended for the roughly 10 percent of adults who have not yet received a Covid-19 vaccine.
